Business
Incanthera plc – Corporate Update & Board Changes
ImmuPharma PLC has noted an announcement from Incanthera plc regarding corporate updates and board changes, specifically that Tim McCarthy has stepped down as Executive Chairman of Incanthera. This development is the primary focus of the announcement, with no other financial figures or operational details provided by ImmuPharma in this RNS. Disclaimer*
About this update from Immupharma Plc
RNS REACH: RELEASE 4 June 2026 ImmuPharma PLC ("ImmuPharma" or the "Company") Incanthera plc - Corporate Update & Board Changes ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development company, notes today's announcement by Incanthera plc, "Incanthera", regarding a corporate update and subsequent Board changes. As part of the Board changes, Tim McCarthy has stepped down as Executive Chairman of Incanthera: Link: https://incanthera.com/ news-media/. Ends ImmuPharma PLC (www.immupharma.co.uk.) Tim McCarthy, Chief Executive Officer and Chairman Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496 SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney SI Capital (Joint Broker) Nick Emerson +44 (0) 203 368 8974 +44 (0) 203 650 3650 +44 (0) 1483 413500 Notes to Editors About ImmuPharma PLC ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. For additional information about ImmuPharma please visit www.immupharma.co.uk. ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895. About Reach announcements Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media onl...